Amgen Inc. $AMGN is Mizuho Markets Cayman LP’s 4th Largest Position

Mizuho Markets Cayman LP lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 490,470 shares of the medical research company’s stock after buying an additional 4,823 shares during the period. Amgen comprises approximately 6.9% of Mizuho Markets Cayman LP’s portfolio, making the stock its 4th biggest position. Mizuho Markets Cayman LP owned about 0.09% of Amgen worth $138,411,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its position in Amgen by 435.8% during the third quarter. Caitong International Asset Management Co. Ltd now owns 284 shares of the medical research company’s stock valued at $80,000 after buying an additional 231 shares during the period. Stance Capital LLC boosted its position in Amgen by 28.4% during the 3rd quarter. Stance Capital LLC now owns 5,730 shares of the medical research company’s stock worth $1,617,000 after acquiring an additional 1,267 shares during the period. Provident Investment Management Inc. boosted its position in Amgen by 1.4% during the 3rd quarter. Provident Investment Management Inc. now owns 4,670 shares of the medical research company’s stock worth $1,318,000 after acquiring an additional 65 shares during the period. Advisory Services Network LLC grew its stake in Amgen by 6.0% during the 3rd quarter. Advisory Services Network LLC now owns 33,551 shares of the medical research company’s stock valued at $9,468,000 after acquiring an additional 1,903 shares in the last quarter. Finally, San Luis Wealth Advisors LLC grew its stake in Amgen by 76.6% during the 3rd quarter. San Luis Wealth Advisors LLC now owns 1,694 shares of the medical research company’s stock valued at $478,000 after acquiring an additional 735 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

Amgen Trading Down 1.4%

Shares of NASDAQ AMGN opened at $361.13 on Wednesday. The business has a 50 day simple moving average of $359.26 and a 200 day simple moving average of $326.77. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The stock has a market cap of $194.67 billion, a price-to-earnings ratio of 25.38, a PEG ratio of 3.63 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AMGN. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Daiwa Securities Group lifted their target price on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Finally, BMO Capital Markets boosted their price target on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.